Business
electroCore Announces Full Year 2025 Financial Results and Organizational Changes
Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription
About this update from Electrocore, Inc.
[{"type":"text","content":"Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (\"electroCore\" or the “Company”), a bioelectronic technology company, today announced full year 2025 financial results. Reported record full year of 2025 revenue of $32.0 million, an increase of approximately 27% over full year of 2024.Cash, cash equivalents, and marketable securities (“Total Cash”) of $11.6 million at December 31, 2025.Full year 2026 revenue guidance of approximately 30% annual growth.Announced Chief Executive Officer, Dan Goldberger will retire effective April 1, 2026, and Joshua Lev will be taking on the role of interim President and Chief Financial Officer.Hired Michael Fox as Chief Operating Officer, strengthening the sales management team through his strong track record of driving significant revenue growth across the VA system and other key channels. Full Year 2025 Financial Results and 2026 Select Guidance For the year ended December 31, 2025, electroCore reported net sales of $32.0 million compared to $25.2 million during the same period in 2024, which represents an approximate 27% increase over the prior year. The increase of $6.8 million is primarily due to an increase in net sales of prescription gammaCoreTM and Quell® Fibromyalgia in the United States and TruvagaTM handsets in the general wellness channel. (in thousands) Full year ended December 31, Channel: 2025 2024 % ChangeUnited States – Rx $24,073 $19,307 25%TAC-STIM 422 1,197 -65%Outside the United States 1,892 1,785 6%In-License / Other 96 82 17%General Wellness 5,549 2,811 97%Total Net Sales $32,032 $25,182 27% Gross profit increased $6.4 million to $27.8 million for the year ended December 31, 2025, compared to the year ended December 31, 2024. The increase in gross profit is attributable to the increased net sales and favorable product mix. Gross margin was 87% for full year 2025 as compared to 85% for the full year of 2024. Research and developmen...